Current studies have shown a difference in serum apelin level between diabetic and/or obese patients and the control group, which supports the role of apelin in diabetes and obesity development and emphasizes the use of apelin as a clinical marker in diabetes and obesity. The gene discussed is APLN; the disease is obesity due to melanocortin 4 receptor deficiency.